Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
ADNOC Gas Targets Up to $4B Profit in 2026 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
CAMBRIDGE, Mass., Feb. 22, 2018 -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter and full-year 2017 financial results, business highlights and 2018 financial guidance.
| What: | Vericel Corporation Fourth-Quarter 2017 Earnings Call | |
| When: | Monday, March 5, 2018 at 8:30am (EST) | |
| Where: | http://investors.vcel.com/events-presentations | |
| How: | The conference call will be available live in the Investors section of the Vericel website at http://investors.vcel.com/events-presentations. Please access the site at least 15 minutes prior to the scheduled start time in order to download the required audio software if necessary. |
To participate in the live call by telephone, please call (877) 312-5881 and reference Vericel Corporation fourth-quarter 2017 earnings call. If calling from outside the U.S., please use the international phone number (253) 237-1173.
If you are unable to participate in the live call, the webcast will be available at http://investors.vcel.com/events-presentations until March 5, 2019. A replay of the call will also be available until 11:30am (EST) on March 10, 2018 by calling (855) 859-2056, or from outside the U.S. (404) 537-3406. The conference ID is 4899311.
About Vericel Corporation
Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. Vericel is marketing MACI® (autologous cultured chondrocytes on porcine collagen membrane), an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Vericel is also marketing Epicel® (cultured epidermal autografts), a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. For more information, please visit the company's website at www.vcel.com.
Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved.
Global Media Contacts:
David Schull
Russo Partners LLC
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)
[email protected]
Karen Chase
Russo Partners LLC
+1 646-942-5627 (office)
+1 917-547-0434 (mobile)
[email protected]
Investor Contacts:
Chad Rubin
The Trout Group
[email protected]
+1 (646) 378-2947
Lee Stern
The Trout Group
[email protected]
+1 (646) 378-2922
